Search
CRISPR Therapeutics AG
CRSPAdd to Watchlist
47.640USD
+0.090+0.19%
Close 07-29 16:00（ET）Quotes delayed by 15 min
4.59BMarket Cap
LossP/E TTM
Financial Health
Currency: USD Updated: 2026-07-29 The current financial score of CRISPR Therapeutics AG is 6.48, ranking 247 out of 384 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.46M, representing a year-over-year increase of 68.55%, while its net profit experienced a year-over-year increase of 9.61%.
Financials
5.89
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.70
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Operational Efficiency
2.94
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Growth Potential
8.55
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Shareholder Returns
7.33
Free cash flow
Relevant data have not been disclosed by the company yet.